...at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives...

HANSA BIOPHARMA

ABOUT HANSA BIOPHARMA

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which can enable kidney transplantation in highly sensitized patients. The Company has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S.

BROAD PIPELINE IN TRANSPLANTATION AND AUTOIMMUNE DISEASES

Candidate	Indication	Research/ Preclinical	Phase 1	Potentially Pivotal program/ Phase 2	Phase 3	Marketing Authorization	Marketed
	US Kidney transplantation in highly sensitized patients [1,2]	Completed	Completed	Completed	Ongoing		
	Anti-GBM antibody disease (investigator-initiated study)	Completed	Completed	Completed	Planned		
	Antibody mediated kidney transplant rejection (AMR)	Completed	Completed	Ongoing			
	GBS (Guillain Barre Syndrome)	Completed	Completed	Ongoing			
	Duchenne (DMD) & Limb-Girdle (LGMD) (Pre-treatment ahead of gene therapy with Sarepta)	Planned					
	Pompe disease (Pre-treatment ahead of gene therapy with AskBio)	Ongoing					
NiceR	Recurring treatment in autoimmune disease, transplantation and oncology	Ongoing					
EnzE	Cancer immunotherapy	Ongoing					

Completed
Ongoing
Planned

[1] Results from the Phase 1 study have been published, Winstedt el al. (2015) PLOS ONE 10(7)
[2] Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine)
[3] Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund
*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients. A post-approval study will commence in parallel with the launch

STRATEGIC PRIORITIES

1	2	3
Advance platform in new indications and therapeutic areas	**Commercialize Idefirix® in first markets and indications**	**Build organizational capablitlies and expand technology platform**

ANTICIPATED FUTURE MILESTONES



COMPANY FACTS

Founded	2007
Stock Exchange	NASDAQ Stockholm (HNSA)
Headquarter	Lund, Sweden
Operations	Europe and the US
Employees	145 (~2/3 in R&D)
Key Executives	Peter Nicklin, Chairman
	Søren Tulstrup, President & CEO
	Donato Spota, SVP & CFO
	Christian Kjellman, SVP & CSO/COO

MARKET DATA (Q4 2022)

Market Cap	USD ~300m	
52 Week Range	SEK 47-106	
Avg. Daily Turnover	vol. 285k shares	
Shares Outstanding	52m	
Top 5 Shareholders	Redmile Group	20.8%
	Avanza	4.2%
	AP4	4.2%
	NXT2B	4.1%
	Thomas Olausson	3.7%

STOCK CHART (1Y)

KEY FINANCIALS

SEKm	2020	2021	2022
Revenue	6m	34m	155m
R&D cost	-227m	-231m	-346m
Net loss	-421m	-548m	-610m
Cash & Short investment	1,378m	889m	1,496m
Operating Cash Flow	-290m	-481m	-504m
Employees	87	133	150

** Unaudited*

CALENDAR

Feb 2, 2023	Interim Report for January-December 2022
Feb 9, 2023	Mid-cap event, Frankfurt
Feb 23, 2023	Erik Penser Healthcare Seminar, Stockholm
Mar 7, 2023	Redeye Healthcare Seminar Commercialization
Mar 16, 2023	Carnegie Nordic Healthcare Seminar 2023
Mar 30, 2023	2022 Annual Report
April 4, 2023	Guggenheim Healthcare Talks Rare Disease Days
April 20, 2023	Interim Report for January-March 2023
April 20 2023	Redeye investor forum, Gothenburg
April 21 2023	Redeye lunch presentation, Stockholm
April 25 2023	Kempen Life Sciences Conference 2023
May 11, 2023	Erik Penser Company Day
May 11, 2023	Redeye investor forum

CONTACTS

Klaus Sindahl
Head of Investor Relations
M: +46(0)709-298 269
klaus.sindahl@hansabiopharma.com

Stephanie Kenney
VP Global Corp. Affairs
M: +1 (484) 319 2802
stephanie.kenney@hansabiopharma.com

Updated 2022-04-21

Hansa Biopharma AB P.O. Box 785 SE-220 07 Lund, Sweden
www.hansabiopharma.com

IMLIFIDASE – A NOVEL APPROACH TO ELIMINATING PATHOGENIC IgG

Origins from a bacteria *Streptococcus pyogenes*

- Species of Gram-positive, spherical bacteria in the genus *Streptococcus*
- Usually known from causing a strep throat infection

Imlifidase, a unique IgG antibody-cleaving enzyme

- Interacts with Fc-part of IgG with extremely high specificity
- Cleaves IgG at the hinge region, generating one F(ab')2 fragment and one homo-dimeric Fc-fragment



Imlifidase inactivates IgG in 2-6 hours

- Rapid onset of action that inactivates IgG below detectable level in 2-6 hours
- IgG antibody-free window for approximately one week



OUR BUSINESS MODEL



Potential indication universe



*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients.
**) In the US a new study has commenced targeting a BLA filing in 2024

HANSA BIOPHARMA